Last updated on July 2018

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)


Brief description of study

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The primary efficacy assessment will be performed at 105 weeks. The participants who do not enter open-label extension will enter for a long term follow-up period for up to 52 weeks after the last crenezumab dose (Week 153).

Clinical Study Identifier: NCT03114657

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: BN29553 ...

Hospital Italiano
Buenos Aires, Argentina
  Connect »

Reference Study ID Number: BN29553 ...

Universidad Maimonides
Caba, Argentina
  Connect »

Reference Study ID Number: BN29553 ...

Hospital Sirio Libanes
Caba, Argentina
  Connect »

Reference Study ID Number: BN29553 ...

Instituto Geriatrico Nuestra Se ora de las Nieves
Capital Federal, Argentina
3.91miles
  Connect »